Core Viewpoint - The company reported a significant increase in revenue and R&D spending, primarily driven by the sales of its product, Icosapent Ethyl, in China, and ongoing clinical trials for obesity treatment [1] Financial Performance - The company achieved a revenue of 56.446 million RMB for the six months ending June 30, 2025, compared to no revenue in the same period last year [1] - Gross profit stood at 50.49 million RMB [1] R&D Expenditure - R&D expenses rose to 99.082 million RMB, marking a year-on-year increase of 90.89% [1] - The increase in R&D spending was attributed to: - An increase in raw material costs by 18.1 million RMB due to process improvements for Icosapent Ethyl and procurement costs for injection pens used in clinical trials [1] - Additional costs of 29.5 million RMB related to preclinical research, clinical trials, and process improvements, including payments to CDMO for production process enhancements and increased CRO fees for ongoing clinical trials in China [1]
银诺医药-B发布中期业绩 研发开支9908.2万元 同比增加90.89%